A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol.

The synthesis of the structurally unusual heterotricyclic compound 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol (trivially named bananin, BN) from pyridoxylidenephloroglucinol and a theoretical prospect on possible biological activities of BN are presented in this report. Pyridoxylidenephloroglucinol is synthesized by Knoevenagel condensation of the vitamin B6 aldehyde pyridoxal with phloroglucinol. Pyridoxylidenephloroglucinol rearranges to light-yellow (4'RS)-1',4'-dihydrobananin by refluxing in 5M hydrochloric acid. Air oxidation subsequently forms BN in the heat which immediately yields orange-yellow (4'RS)-4'-chloro-1',4'-dihydrobananin by 1,4-addition of hydrogen chloride. This intermediate could be isolated but, interestingly, not a BN hydrochloride. Brown BN is finally achieved by base-catalyzed elimination of hydrogen chloride from (4'RS)-4'-chloro-1',4'-dihydrobananin. Regarding possible biological activities, it was demonstrated that BN acts as zinc (Zn2+) chelator. Therefore, a target of interest could be the human immunodeficiency virus type 1 (HIV-1) zinc finger HIV-1 RNA-binding nucleocapsid protein p7 (NCp7). Through suggested zinc ejection from HIV-1 genomic RNA psi-element-binding and HIV-1-RNA-duplex packaging NCp7 by BN, thus rendering NCp7 functionally obsolete, it is deduced that HIV-1 replication and effective infectious virion encapsidation could be inhibited by BN. Furthermore, theoretical and structural considerations propose that BN is converted into bananin 5'-monophosphate (BNP) by the cell type-ubiquitous human enzyme pyridoxal kinase (EC 2.7.1.35). Together with the putative antilentiviral retinoid vitamin A-vitamin B6 conjugate analogue B6RA (Kesel, A. J. Biochem. Biophys. Res. Comm. 2003, 300, 793), BNP is postulated to serve as effector in a system of protein target sequences RX(D/E) of RNA virus components. Human immunodeficiency Retroviridae (HIVs) could possibly be influenced by B6RA and BNP. In addition, candidate targets of B6RA and BNP could be adsorption, transcription and/or viral RNA replication of an interestingly wide RNA virus selection including Picornaviridae (poliovirus, human coxsackievirus, hepatitis A virus), Flaviviridae (yellow fever virus, Dengue virus, West Nile virus, Kunjin virus, St. Louis encephalitis virus, hepatitis C virus), Togaviridae (rubella virus), Coronaviridae (human coronavirus, human SARS-associated coronavirus), Rhabdoviridae (rabies virus), Paramyxoviridae (human parainfluenza virus, measles virus, human respiratory syncytial virus), Filoviridae (Marburg virus, Ebola virus), Bornaviridae (Borna disease virus), Bunyaviridae (Hantaan virus), Arenaviridae (Lassa virus), and Reoviridae (human rotavirus). The postulated scope of 'metabolically trapped' BNP might resemble the antiviral spectrum of the RNA-viral virustatic ribavirin.

Introduction

Oligo-oxa-adamantanes are rarely found in nature as structurally striking biochemicals. The neurotoxic sodium channel blocker tetrodotoxin (TTX), one of the most toxic non-proteinaceous poisons along with aconitine, veratridine, saxitoxin (STX), batrachotoxin (BTX) and palytoxin (PTX), is widely spread in nature, especially in marine ecosystems. TTX, traditionally esteemed famous for its occurrence in the inner organs (especially liver and ovaries) of the Japanese culinaric delicacy tora fugu, the globe (tiger puffer) fish Spheroides rubripes (Tetraodontidae), is to be depicted as substituted 2,8-dioxa-adamantane (Fig. 1 ).1, 2, 3 Daigremontianin was isolated from the tropical flower Kalanchoe daigremontiana Hamet et Perr. (Crassulaceae) and was shown to be a steroid (bufadienolide) 2,8,9-trioxa-adamantane (Fig. 1).4, 5 Synthetic adamantanes, or tricyclo[3.3.1.13,7]decanes, are used as antiviral chemotherapeutics [amantadine (1-amino-adamantane) and rimantadine systemically against influenza A virus, tromantadine topically against herpes simplex virus type 1 infections] and antiparkinsonian (muscle relaxant) drugs [amantadine as central dopaminergic, memantine (1-amino-3,5-dimethyl-adamantane) as neuroprotective N-methyl-d-aspartate (NMDA)-subtype glutamate receptor antagonist] (Fig. 1).

Figure 1

The natural products tetrodotoxin and daigremontianin with oligo-oxa-adamantane structure and the synthetic adamantanes, or tricyclo[3.3.1.13,7]decanes, amantadine, rimantadine, tromantadine, and memantine.

In addition to the Schiff base formation of pyridoxal (mainly existing as racemic cyclic hemiacetal, especially as hydrochloride) and pyridoxal 5′-phosphate (coenzyme vitamin B6) with primary amino groups of biomolecules which is of central importance in coenzyme vitamin B6-catalyzed biochemical metabolism (transamination, decarboxylation, racemization, ligation, lysis) of amino acid, neurotransmitter, phospholipid, sphingolipid, heme, polyamine and tumor marker synthesis, pyridoxal and pyridoxal 5′-phosphate are capable of undergoing various chemical reactions. Especially Knoevenagel condensations lead to interesting compounds with antiretroviral, oncolytic, immunosuppressant, antioxidative, free radical-scavenging, nitric oxide synthase inhibition and other biological activities.8, 9, 10, 11, 12 Recently, a new conception for inducing selective apoptosis in human immunodeficiency virus type 1 (HIV-1)-infected cells was proposed. Therefore, my attention focused on the analysis of unique reactions of vitamin B6 which was shown to be suitable for various chemical transactions.8, 9, 10, 11, 12

Results and discussion

Infrared absorption spectroscopy of the reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol

An infrared absorption (IR) spectrum of the reaction product was recorded in a solid potassium bromide (KBr) pellet (Fig. 2 ). No α,β-unsaturated, quinoid carbonyl absorption at wavenumbers between 1700 and 1600 cm−1 could be seen. Instead a very broad OH band between 3650 and 1800 cm−1 dominates the IR spectrum. It represents a valence bond vibration of hydrogen-bonded O–H, and, respectively, intra/intermolecular polymeric associated chelate O–H. At 2900 cm−1 a methyl group C–H and at 2825 cm−1 a methylene group C–H valence bond vibration can be identified. At 1590 and 1520 cm−1 C–C aromatic valence bond vibrations of a pyridine heterocycle can be detected. At wavenumbers of 1430 cm−1 a methylene C–H deformation vibration and 1395 cm−1 a methyl group C–H deformation vibration can be analyzed. Very characteristic is the aromatic C–O phenolic valence bond vibration at 1210 cm−1. The two bands at 1065 cm−1 (Ar–CH2–OH) and 1110 cm−1 are aliphatic C–O valence bond vibrations. The absorption band at 820 cm−1 is fitting to a 1,2,3,4-tetrasubstituted aromate with one isolated CH. Taken together, already the IR data unequivocally proof the unusual 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol structure because the 6-hydroxy-4-(hydroxymethyl)-1-methyl-8H-[1]benzopyrano[2,3-c]pyridin-8-one alternative would have a strong α,β-unsaturated, quinoid carbonyl absorption between wavenumbers of 1775 and 1650 cm−1 (preferably 1650–1700 cm−1, p-benzoquinone 1669 cm−1). The predominant, very broad OH band from 3650 to 1800 cm−1 peaking at 3350 cm−1 pointed to strongly associated intermolecular hydrogen bonds in the solid state of the brown substance KBr pellet. A similar effect was observed in the IR spectrum (in KBr) of the polyhydroxyl, solvent-retaining compound tetrodotoxin.

Figure 2

Infrared (IR) absorption spectrum measured in potassium bromide (KBr) solid disc of the unknown brown-black reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol.

UV spectrophotometry of the reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol

An UV electronic absorption spectrum of the substance was recorded in 0.1 M sodium hydroxide solution (Fig. 3 ). The solubility of the material in water, ethanol, or dilute acid [dilute hydrochloric (HCl) and sulfuric acid (H2SO4)] is too low to work in these solvents. The product is soluble in sodium hydroxide solution and dimethyl sulfoxide (DMSO) to give yellow to brown solutions. The UV spectrum showed two maxima at 220.0 nm (ε=22,443 L mol−1 cm−1) and 285.8 nm (ε=11,591 L mol−1 cm−1), the molar mass for the calculation of the molar extinction coefficient ε was choosed as M=327.29 g/mol, the theoretic molar mass of 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol (Fig. 3). This result can be reasonably interpreted in the way that a typical sodium phenolate [sodium phenolate in water: λ1,max=235 nm (ε=9400), λ2,max=287 nm (ε=2600)] is the chromophor of the compound. The structure 6-hydroxy-4-(hydroxymethyl)-1-methyl-8H-[1]benzopyrano[2,3-c]pyridin-8-one would show an electronic absorption maximum at a wavelength of approximately 450 nm similar to the α,β-unsaturated carbonyl condensate B6PR. Therefore, the UV spectrophotometry supplies us with strong evidence for 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol to represent the UV chromophor of the unknown product. Already now the spectral-analytic structure determination provides growing proof for being 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxatricyclo[3.3.1.13,7]decane-3,5,7-triol the suspected structural composition of the material in question.

Figure 3

UV electronic absorption spectrophotometry of the unknown brown-black reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol. For this purpose, 0.70 mg substance were dissolved in an 100.00 mL volume of 0.1 M sodium hydroxide (NaOH) solution. The maximal absorption of the yellow solution stayed in the linear range of the spectrophotometer (A <0.8).

Proton nuclear magnetic resonance (1H NMR) spectroscopy of the reaction product resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol

The final structural proof could be made by examination of the 1H NMR spectrum of the substance in deuterated chloroform (CDCl3) (Fig. 4 ). At the chemical shift δ 2.50 a singlet of three protons of the heteroaromatic methyl group peaked. At δ 3.32 six protons of the methylene groupings of the trioxa-adamantane-triol could be unequivocally identified. At δ 4.85 (m, 2H, pyridine CH 2OH) and δ 5.90 (m, 1H, CH2OH) the intermolecular-associated hydroxymethyl group gave broadened multiplets emerging possibly from interaromatic charge-transfer complexation and hydrogen-bonding. At δ 8.11 one heteroaromatic proton proofed to complete that no other structural composition was possible than 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxatricyclo[3.3.1.13,7]decane-3,5,7-triol. Ethanol, water, and the educt pyridoxylidenephloroglucinol were detectable as trace impurities from synthesis.

Figure 4

1H NMR spectrum of bananin in CDCl3. The bananin contained as impurities the synthesis solvents ethanol [δ 1.18 (t), 3.59 (q)] and water [in CDCl3 δ 1.28 (s)]. Additionally, traces of the synthesis educt pyridoxylidenephloroglucinol [δ 2.70 (s, CH3), 5.37 (d, CH2OH), 6.42 (s, HO–CCH–CO), 6.60 (s, HO–CCH–CO), 7.13 (s, arCHR), 8.89 (s, pyridine CH)] were detectable.

Conclusion

Structural, supramolecular and physicochemical aspects of BN

Since the organic chemical structure of the material resulting from the heat and hydrochloric acid treatment of pyridoxylidenephloroglucinol could be defined by the analytical results, an experimentally based scheme for the chemical reactions leading to the synthesis of 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxatricyclo[3.3.1.13,7]decane-3,5,7-triol is depicted (Fig. 5 ). The hypothesis that bananin is an highly intermolecular-associated material, leading to a nearly black colour through interaromatic charge-transfer complexation between the pyridine heterocycles and hydrogen-bonding between the trioxa-adamantane-triol heterotricycles is supported by combination of the IR, UV, and 1H NMR data (Fig. 6 ). An instruction protocol for the isolation of amorphous bananin picrate was developed. Amorphous bananin picrate is soluble in water with intense yellow colour and liberates brown-black amorphous bananin by treatment with strong bases (NaOH solution). The intermolecular network leading to the black colour of bananin is interrupted in the yellow bananin picrate (Fig. 6) by complexing the pyridine heterocycle with picric acid. Furthermore, a sodium hydroxide-containing solution of bananin monosodium salt in water both forms a blue copper complex with Cu(OH)2 and a white zinc complex with Zn(OH)2. It is proposed that bananin behaves as bidentate chelate donor to build the tetragonal-planar coordination complex (SP-4-1)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O 2,O 3‘]copper (Fig. 7 ) and the tetrahedral coordination complex (T-4)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O 2,O 3‘]zinc (Fig. 7). In addition, it should be mentioned that bananin has lost most of its vitamin B6 character. The pyridine nitrogen is less basic than in pyridoxal and the UV parameters of pyridoxine/pyridoxal are left. Instead a typical phenolic behaviour is found and the tendency of vitamin B6 to exist mostly in a well-defined zwitterionic state at physiologic pH 7.4 is abandoned in bananin.

Figure 5

Chemical synthesis of 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol. The Knoevenagel condensation of phloroglucinol and pyridoxal hydrochloride yields pyridoxylidenephloroglucinol. Its heat treatment with 5 M hydrochloric acid firstly produces light yellow (4′RS)-1′,4′-dihydrobananin. Subsequently air oxidation in the heat precipitates the orange-yellow (4′RS)-4′-chloro-1′,4′-dihydrobananin which results from addition of hydrogen chloride to bananin. (4′RS)-4′-chloro-1′,4′-dihydrobananin eliminates hydrogen chloride by treatment with strong bases (NaOH). Finally, the brown-black bananin is isolated by help of its relative insolubility in water.

Figure 6

Left, excerpt of the intermolecular association of black bananin leading to supramolecular chains including charge-transfer complexes between the aromatic rings and strong hydrogen-bonding between OH groups (red arrows) and the trioxa-adamantane-triol cages (magenta-green). Right, chemical structure of the yellow bananin picrate.

Figure 7

Proposed chemical composition of the cupric complex of bananin, the tetragonal-planar bidentate chelate (SP-4-1)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O2,O3‘]copper [bis(bananinato)copper, bisBNcopper], and the zinc complex of bananin, the presumably tetrahedral bidentate chelate (T-4)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O2,O3‘]zinc [bis(bananinato)zinc, bisBNzinc].

Intracellular enzymatic phosphorylation of BN to BNP by human pyridoxal kinase

To move a step toward the direction of possible biological activities of BN it is suggested that human pyridoxal kinase accepts BN as a substrate for ATP- and Zn2+-dependent phosphorylation to bananin 5′-phosphate (BNP) (Fig. 8 ). Pyridoxal kinase can phosphorylate an array of vitamin B6-derivatives with modulated substituents in position 4 of the pyridine heterocycle, additionally to its natural substrates pyridoxine, pyridoxal and pyridoxamine.14, 15 This was theoretically proofed by the crystal structure determination of sheep brain pyridoxal kinase16 which shows a tight binding of the 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine vitamin B6 core structure of pyridoxal in the substrate-binding pocket, but structural fill space at the 4-position of the vitamin B6 core element. Conclusively, it is reasonable to speculate that BN is converted into BNP by the human tissue-ubiquitous pyridoxal kinase, and such is ‘metabolically trapped’ inside the cell after cellular uptake by vitamin B6 carrier systems. Through usage of vitamin B6 metabolic systems high intracellular concentrations of BNP could be achieved since the phosphate group-induced zwitterionic, hydrophilic appearance of BNP prevents reverse cell membrane passage.

Figure 8

Enzymatic intracellular phosphorylation of BN to BNP by human pyridoxal kinase resulting in ‘metabolic trapping’ of BNP inside the cell.

Biological significance of zinc complexation by BN for zinc ejection from HIV-1 nucleocapsid protein NCp7

The HIV-1 gag gene polycistronic mRNA product encodes the myristoylated matrix protein p17, the phosphorylated p24 core protein, the small core peptide p2, the zinc-containing nucleocapsid protein NCp7, the small core peptide p1, and the virion-incorporated core link protein p6. NCp7 contains two highly conserved nonclassical Cys-Xaa2-Cys-Xaa4-His-Xaa4-Cys (CCHC) zinc finger motifs.17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 This retroviral zinc finger motif is conserved in all onco- and lentiretroviruses except spumaretroviruses. NCp7 binds to the duplex of HIV-1 retrogenomic mRNA encapsidated in the mature virion core at the highly secondary-structured HIV-1 RNA sequence elements known as ψ-packaging signal near the 5′-LTR, next to the tRNALys primer binding (PB) site. The two zinc fingers are sensitive to organic-chemical zinc chelating compounds. 3-Nitrosobenzamide (NOBA)17, 18, 19 and other small molecule compounds25, 26, 27, 28, 31, 32, 33, 35 eject zinc from NCp7 holoprotein leaving a functionally deprived apoprotein. Therefore, zinc chelators are able to inhibit HIV-1 replication and infectivity in vitro17, 18, 19, 21, 23 and in vivo. BN is an excellent zinc chelator and is postulated to be chemically suitable for zinc ejection from HIV-1 NCp7 (Fig. 9 ).

Figure 9

Postulated zinc ejection from HIV-1 (isolate HXB2) RNA-binding NCp7 holoprotein zinc finger sequence motifs I and II (yellow: l-cysteine, black: conserved hydrophobic l-amino acids, magenta: coordinatively Zn2+-bound l-histidine moieties) by four BN to yield defunctional NCp7 apoprotein, devoid of two Zn2+ cations, and two bisBNzinc.

Proposed active ester formation of BNP at selected RNA-viral protein RX(D/E) target sequences

In analogy to the postulated antiviral mechanism of the retinoid vitamin A-vitamin B6 conjugate analogue B6RA at RGD and RLE viral protein target sequences, a covalent 1,4-dihydro-4-pyridinyl active ester formation of BNP with RGD aspartic acid residues in RNA-viral protein target sequences is proposed (Fig. 10 ). BNP should have a similar salt-bridge amphoteric affinity to RX(D/E) protein sequence motifs like B6RA. Therefore, it could covalently bind to viral RX(D/E) sequences and, analogously to B6RA, chemically modify important viral proteins, thus making them functionally obsolete. Together with the putative antilentiviral retinoid vitamin A–vitamin B6 conjugate analogue B6RA, BNP is proposed to serve as effector in a system of protein target sequences RX(D/E) of RNA virus components. Human immunodeficiency virus type 1 (HIV-1) trans-activating transcriptional regulatory protein Tat sequences PRGDP and PRLEP were suggested as possible targets of B6RA. I propose a binding of B6RA/BNP to Tat PRGDP tat exon 2-encoded C-terminal sequence which serves also for cross-talk with cellular tumor suppressor protein p53. BNP could form an active ester at the tat exon 2-encoded C-terminal PRGDP sequence (Fig. 10) by addition of the aspartate (d) residue to the trioxa-adamantane-triol 4-substituent-activated pyridine heterocycle in BNP (Fig. 10). This 1,4-dihydro-4-pyridinyl active ester species would be principally able to cross-link Tat d-amide-like to amino groups of DNA nucleobases (adenine, guanine, cytosine) in HIV-1 proviral integrated U3/R sequences of HIV-1 5′-long terminal repeat or, more generally, in host cellular DNA. In this way, non-repairable Tat protein–DNA complexes would serve as trigger for DNA damage-induced apoptosis selectively in cells in which Tat is present. As a result the host organism would be specifically extricated from integrated HIV-1 proviruses. A database search and most recent status Medline/PubMed search for RGD-similar sequences was performed for human RNA viruses (Table 1 ). The most important human RNA virus pathogens were considered. Surprisingly, many indispensable virus proteins contain often conserved B6RA- and BNP-binding triplets RX(D/E) which are frequently surrounded by hydrophobic protein sequence strips enhancing affinity for the B6RA hydrophobic vitamin A chain (Table 1). Candidate targets of B6RA and BNP were found within proteins of RNA viruses like Picornaviridae (poliovirus, human coxsackievirus, hepatitis A virus), Flaviviridae (yellow fever virus, Dengue virus, West Nile virus, Kunjin virus, St. Louis encephalitis virus, hepatitis C virus), Togaviridae (rubella virus), Coronaviridae (human coronavirus, human SARS-associated coronavirus), Rhabdoviridae (rabies virus), Paramyxoviridae (human parainfluenza virus, measles virus, human respiratory syncytial virus), Filoviridae (Marburg virus, Ebola virus), Bornaviridae (Borna disease virus), Bunyaviridae (Hantaan virus), Arenaviridae (Lassa virus), Reoviridae (human rotavirus), and Retroviridae (HIV-1). The antiviral scope of B6RA/BNP may be related to the broad-spectrum anti-RNA-viral virustatic ribavirin because ribavirin is mostly active against RNA viruses by inhibiting inosine 5′-monophosphate dehydrogenase as ribavirin 5′-monophosphate, and mRNA precursor 5′-capping as ribavirin 5′-triphosphate. The actual therapeutic value of the B6RA/BNP system for chemotherapeutic treatment of RNA-viral human disease conditions remains elusive until comprehensive experimental verification is gained.

Figure 10

Example of a proposed covalent active ester formation of BNP at a selected, representative RNA-viral, HIV-1 trans-activating transcriptional regulatory Tat protein RGD sequence (see Table 1) by addition of the aspartate group to the pyridine ring of RGD-ionic contact (IC)-bound BNP resulting in an activated 1,4-dihydro-4-pyridinyl ester.

Table 1

Selection of RNA virus B6RA/BNP-affinity protein sequence motifs RX(D/E)

Virus	Virus Family	Strain	Virus Protein	B6RA/BNP
	Subfamily			Target Sequence
	Genus
Polio type 1	Picornaviridae	Mahoney, Sabin	3D	2006-FGDRVDYI-2013
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Polio type 2	Picornaviridae	Lansing, P712	3D	2004-FGDRVDYI-2011
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Polio type 3	Picornaviridae	Sabin vaccine	3D	2003-FGDRVDYI-2010
	Enterovirus	P3/Leon/37,	RNA-dependent
		Sabin vaccine	RNA
		P3/Leon/12a[1]b,	Polymerase
		23127
Polio type 1	Picornaviridae	Mahoney, Sabin	3D	2125-FFRADEKYPFLI-2136
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Polio type 2	Picornaviridae	Lansing	3D	2123-FFRADEKYPFLV-2134
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Polio type 3	Picornaviridae	Sabin vaccine	3D	2122-FFRADEKYPFLI-2133
	Enterovirus	P3/Leon/37,	RNA-dependent
		Sabin vaccine	RNA
		P3/Leon/12a[1]b,	Polymerase
		23127
Human Coxsackie A9	Picornaviridae	Griggs	3D	2113-FLKRYFRADEQYPFLV-2128
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Human Coxsackie A24	Picornaviridae	EH24/70	3D	2126-FLKRFFRADEKYPFLV-2141
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Human Coxsackie B1	Picornaviridae	Japan	3D	2094-FLKRYFRADEQYPFLV-2109
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Human Coxsackie B3	Picornaviridae	Nancy	3D	2097-FLKRYFRADEQYPFLV-2112
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Human Coxsackie B4	Picornaviridae	E2, JVB / Benschoten / New York/51	3D	2095-FLKRYFRADEQYPFLV-2110
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Human Coxsackie B5	Picornaviridae	1954/UK/85	3D	2097-FLKRYFRADEQYPFLV-2112
	Enterovirus		RNA-dependent
			RNA
			Polymerase
Human Severe Acute Respiratory Syndrome (SARS) Corona	CoronaviridaeCoronavirus	Tor2, CUHK-W1, Urbani	Putative NSP9 in ORF1ab Polyprotein RNA-dependent RNA Polymerase	4470-FFKFRVDGDMVP-4481
Human Severe Acute Respiratory Syndrome (SARS) Corona	CoronaviridaeCoronavirus	Tor2, CUHK-W1, Urbani	Putative NSP10 in ORF1ab Polyprotein Metal-binding NTPase Helicase	5634-IIPARARVECFDKFKV-5649
Rabies	Rhabdoviridae	Pasteur / PV, SAD B19	L	150-VLSCLERVDYDNAF-163
	Lyssavirus		RNA-directed	659-WIYYSDRSDLIGL-671
			RNA
			Polymerase
			5‘-RNA
			Capping
			Poly—
			Adenylation
Rabies	Rhabdoviridae Lyssavirus	Pasteur / PV, SAD B19, ERA, Street, HEP-FLURY, vnukovo-32	G Spike Membrane Glycoprotein Precursor	276-LVNLHDFRSDEIEHLV-291
Human	Paramyxoviridae	NIH 47885,	HN	272-PKVDERSDYASS-283
Parainfluenza	Paramyxovirinae	Wash/1511/73,	Hemagglutinin—
type 3	Respirovirus	Aus/124854/74,	Neuraminidase
		Wash/641/79,
		Tex/545/80,
		Tex/9305/82,
		Tex/12677/83
Measles	Paramyxoviridae Paramyxovirinae Morbillivirus	Edmonston, edmonston-zagreb, Halle, edmonston b, philadelphia-26, leningrad-16, Yamagata-1	F Fusion Membrane Glycoprotein Precursor	437-YPDAVYLHRIDLGPPISL-454450-PPISLERLDVGTNLG-464
Measles	Paramyxoviridae Paramyxovirinae Morbillivirus	Edmonston, Rubeovax, Moraten, AIK-C, HU2, SE, Schwarz vaccine, CL, TT	M Viral Matrix Protein	186-VAFNLLVTLRIDKAIGP-202
Human Respiratory Syncytial A	Paramyxoviridae Pneumovirinae Pneumovirus	A2	L RNA-directed RNA Polymerase Protein Kinase	917-YRGESLLCSLIF-928
Human Respiratory Syncytial A / B	Paramyxoviridae Pneumovirinae Pneumovirus	A2, Long, subgroup B/strain 18537	P Phosphoprotein L/N-binding mRNA 5‘-Capping and Polyadenylation	131-ITARLDRIDEKLSEIL-146
Marburg	Filoviridae	Musoke, Popp	NP	558-PPPPLYAQEKRQDPIQHP-575
	Filovirus		Nucleocapsid
	Marburg virus		Major
			Nucleoprotein
Marburg	Filoviridae	Musoke	L	1169-LLPYDCKELRLEGS-1182
	Filovirus		RNA-directed	1763-ITKHDQRCEREESSP-1777
	Marburg virus		RNA
			Polymerase
			mRNA
			5′-Capping and
			Polyadenylation
Marburg	Filoviridae	Musoke, Popp	M/VP40	262-MMKKRGENSPVVYF-275
	Filovirus		Viral Matrix Protein
	Marburg virus
Human Hepatitis A	Picornaviridae Hepatovirus	HM-175 wild type, 18F, 24A, 43C, LA, MBB	2C Initiation of RNA Synthesis	1216-AMVTRCEPVVCYL-1228
Yellow Fever	Flaviviridae	17D,	NS5	2638-IHRLEPVKCDTLL-2650
	Flavivirus	Pasteur	RNA-dependent	3148-SVLTRLEAWLT-3158
		17D-204	RNA
			Polymerase
Dengue type 1	Flaviviridae	Singapore	NS3	2011-LMRRGDLPVWLSY-2023
	Flavivirus	S275/90	Protease
			NTP-Binding
			Helicase
Dengue type 2	Flaviviridae	Jamaica, 16681,	NS3	2011-LMRRGDLPVWLAY-2023
	Flavivirus	PR159/S1,	Protease
		16681-PDK53,	NTP-Binding
		New Guinea-C, Tonga 1974	Helicase
Dengue type 3	Flaviviridae	—	NS3	2010-LMRRGDLPVWLAH-2022
	Flavivirus		Protease
			NTP-Binding
			Helicase
Dengue type 4	Flaviviridae	—	NS3	2009-LMRRGDLPVWLSY-2021
	Flavivirus		Protease
			NTP-Binding
			Helicase
West Nile	Flaviviridae	WN-NY99	E/V3	370-AHNDKRADPAFVC-382
	Flavivirus		Membrane—
			Associated Viral Envelope
			Glycoprotein
Kunjin	Flaviviridae	MRM61C	E	370-AHNDKRADPSFVC-382
	Flavivirus		Membrane—
			Associated Viral Envelope
			Glycoprotein
St. Louis	Flaviviridae	MS1-7	E	368-AHNTKRSDPTFVC-380
Encephalitis	Flavivirus		Major
			Envelope
			Protein
Hepatitis C	Flaviviridae Hepacivirus	1, BK, J, Taiwan, Japanese, H77, HCV-1, H, JK1, JK5, HC-JT	E2/NS1 Glycosylated Membrane Protein	646-WTRGERCDLEDRDR-659
Rubella	Togaviridae	Therien	NSP1-2	494-CACAPRCDVPRERPSAP-510
	Rubivirus		Nonstructural
			Polyprotein
			5‘-Cap
			Methyltransferase
			Zn2+-Cysteine
			Protease
Rubella	Togaviridae Rubivirus	Therien, HPV77 vaccine, RA27/3 vaccine	C Structural Polyprotein Nucleocapsid Protein	165-AVFYRVDLHFTNLGTPP-181
Human Corona	Coronaviridae	229E	S/E2	94-FVYFNGTGRGDCKGFSSDV-112
	Coronavirus		Surface Spike	257-SVINRLRCDQLSFDVP-272
			Glycoprotein	636-ALRNSARLESADVSEML-652
			Precursor	1016-VTFVNISRSELQTIVP-1031
			Aminopeptidase N-binding	1099-LVDLKWLNRVETYIKWP-1115
Marburg	Filoviridae	Musoke, Popp	VP30	160-YLHRSEIGNWM-170
	Filovirus		Phosphorylated Nucleocapsid Protein
	Marburg virus
Marburg	Filoviridae	Musoke, Popp	VP24	197-FLVEVRRIDIEPCC-210
	Filovirus		Membrane-associated Structural Protein
	Marburg virus
Ebola	Filoviridae	Mayinga,	NP	103-GFRFEVKKRDGV-114
	Filovirus	Zaire-95,	Nucleocapsid	108-VKKRDGVKRLEELLPAV-124
	Ebola virus	Gabon-94	Major
	Zaire		Nucleoprotein
Ebola	Filoviridae	Mayinga	P/VP35	292-PPVIHIRSRGDIPRAC-307
	Filovirus		Polymerase Complex Protein (Minor
	Ebola virus		Nucleoprotein)
	Zaire
Borna Disease	BornaviridaeBornavirus	He/80, He/80/FR, V, V/FR, H1766, No/98, CRNP5, CRP3A, CRP3B	P/p23Nucleocapsid Phosphorylated P-Protein	99-DISARIEAGF-108116-VETIQTAQRCDHSDSIR-132
Borna Disease	BornaviridaeBornavirus	He/80, He/80/FR, V, V/FR, H1766, CRNP5, CRP3A, CRP3B	N/p40Nucleocapsid Nucleic Acid-bindingN-Protein	100-YLSTPVTRGEQTVV-113339-YRRREISRGEDGAELS-354
Hantaan	Bunyaviridae	76-118, 84Fli, A16	M Polyprotein	420-VNFVCQRVDMDIVVYC-435
	Hantavirus		Segment/
			Glycosylated
			Membrane
			G1 Protein
Hantaan	Bunyaviridae	R22	M Polyprotein	418-ISFICQRVDMDIIVYC-433
	Hantavirus		Segment/
			Glycosylated
			Membrane
			G1 Protein
Lassa	Arenaviridae	Josiah	NP S Segment	113-VIRTERPLSAGVYM-126
	Arenavirus		Major Structural
	Old World		Nucleoprotein
	Arenaviruses		Nucleocapsid
			Component
Lassa	Arenaviridae	GA391 Nigeria	NP S Segment	113-VTRTERPLSSGVYM-126
	Arenavirus		Major Structural
	Old World		Nucleoprotein
	Arenaviruses		Nucleocapsid
			Component
Human Rota	Reoviridae	KU	VP4/VP5	336-FSVSRYEVIKENSYVYV-352
group A	Rotavirus		Outer Layer	482-PIMNSVTVRQDLERQL-497
	Rotavirus A		Surface Protein	733-YGITRIEALNLI-744
	Human		Hemagglutinin	760-PIIRNRIEQLILQC-773
	Rotavirus A		Fusion Protein
Human Immunodeficiency	Retroviridae	HIV-1 Reference Genome,	TatTrans-activating Transcriptional	1-MEPVDPRLEPW-11
type 1	Lentivirus	HTLV-III/LAV, HXB2, BRU, PV22, RF/HAT	RegulatoryProtein	73-PTSQPRGDPTGP-84
Human Immunodeficiency	Retroviridae	HXB3, BH10, Clone 12	TatTrans-activating Transcriptional	1-MEPVDPRLEPW-11
type 1	Lentivirus		Regulatory	73-PTSQSRGDPTGP-84
			Protein
Human Immunodeficiency	Retroviridae	HIV-1 Reference Genome,	Vif (Sor)	129-VSPRCEYQA-137
type 1	Lentivirus	HTLV-III/LAV, HXB2, BRU, PV22, RF/HAT, BH10, Clone 12	Viral Infectivity FactorAccessoryProtein
Human Immunodeficiency	Retroviridae	HIV-1 Reference Genome,	Nef/p27	13-WPTVRERMRRAEPAA-27
type 1	Lentivirus	HTLV-III/LAV, HXB2, BRU	Negative Factor	100-LIHSQRRQDILDLWIY-115
			Anti-apoptotic Accessory
			Protein

Experimental

Synthesis of pyridoxylidenephloroglucinol from pyridoxal hydrochloride and phloroglucinol

A mass of 20.81 g pyridoxal hydrochloride (M=203.63 g/mol) (n=102.1952 mmol) was dissolved in 63 mL water by heating on a water bath. 12.89 g phloroglucinol (M=126.11 g/mol) (n=102.2123 mmol) were dissolved in 79 mL of ethanol 90% by heating on a water bath. The two solutions were mixed and refluxed for 10 min. Then 8.59 g sodium bicarbonate (NaHCO3) (M=84.01 g/mol) (n=102.2497 mmol) were added to the hot yellow solution. A bright yellow precipitate formed after approximately 10 min on reflux. The suspension was additionally heated for 5 min on a water bath, cooled slowly to room temperature, and freezed to −18° C for 4 h. Then the precipitate was vacuum filtered and transferred and washed with 65 mL water. It was dried over anhydrous calcium chloride (CaCl2) in a vacuum desiccator. Yield: 28.1 g yellow powder (100%) pyridoxylidenephloroglucinol C14H13NO5 (M=275.26 g/mol).

Synthesis of 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) from pyridoxylidenephloroglucinol

28.1 g pyridoxylidenephloroglucinol (M=275.26 g/mol) (n=102.0853 mmol) were suspended in 100 mL of 5 M hydrochloric acid (500 mmol HCl). The dark yellow solution was refluxed for 15 min on a water bath. A caramel-yellow coloured precipitate of 1′,4′-dihydrobananin formed. Then it was heated to 170-180° C on an air bath and the orange-yellow (4′RS)-4′-chloro-1′,4′-dihydrobananin formed in the heat. When the reaction proceeds the heat is reduced to 120° C and then the mixture was cooled slowly to room temperature. Then it was freezed to −18° C for 12 h. The nearly solid orange-yellow suspension was filtered through a paper filter. The yellow-orange residue was suspended in 300 mL saturated (room temperature θ=20 °C) sodium bicarbonate (NaHCO3) solution in water. The orange-yellow (4′RS)-4′-chloro-1′,4′-dihydrobananin eliminated HCl to form bananin. Then solid sodium hydroxide (NaOH) pearls were added in small portions to the suspension until all material had dissolved to form a coffee-black solution (V=400 mL) of bananin sodium salt. It was titrated in small portions with 10 M hydrochloric acid until brown bananin precipitated. The chocolate brown suspension was left standing at room temperature for 3 days. After that time the suspension was filtered through a paper filter and the chocolate brown residue in the filter was washed with 400 mL water. It was dried for 2 weeks over anhydrous calcium chloride (CaCl2) in a vacuum desiccator. Yield: 33.2 g brown-black powder (99%) 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) C14H17NO8 (M=327.29 g/mol). IR (KBr) (wavenumber in cm−1): 3350 (very broad, ν O–H, s), 2900 (ν C–H, CH3, w), 2825 (ν C–H, CH2, w), 1590 (ν CC, pyridine, m), 1520 (ν CC, pyridine, m), 1430 (δ C–H, CH2, m), 1395 (δ C–H, CH3, m), 1270 (ν C–O–C, w), 1210 (ν arC–OH, m), 1110 (ν C–OH, w), 1065 (ν C–O, CH2OH, w), 1020 (ν C–OH, w), 900 (w), 820 (δ pyridine C–H, w), 740 (δ CH2, rocking, w). UV (0.1 M NaOH solution): λmax,1=220.0 nm [ε=22,443 L mol−1 cm−1; A (1%/1 cm)=686], λmax,2=285.8 nm [ε=11,591 L mol−1 cm−1; A (1%/1 cm)=354]. 1H NMR (CDCl3): δ 2.50 (s, 3H, pyridine CH3), 3.32 (s, 6H, CH2), 4.85 (m, 2H, pyridine CH 2OH), 5.90 (m, 1H, CH2OH), 8.11 (s, 1H, pyridine CH).

Qualitative preparation of amorphous 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol picrate (amorphous bananin picrate)

A saturated solution (50 mL at 80° C) of 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) in dimethyl sulfoxide (DMSO) was mixed with 50 mL of a saturated (room temperature θ=20 °C) solution of picric acid (2,4,6-trinitrophenol) in 50% ethanol. Then 200 mL 90% ethanol and 500 mL water were added in the heat. A voluminous yellow precipitate formed. The temperature of the suspension was kept at −18 °C for 12 h. The precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl2) in a vacuum desiccator. Yield: yellow powder of crude (bananin-containing) 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol picrate (bananin picrate). Purification: the crude product was dissolved in 200 mL 5 M hydrochloric acid (1 mol HCl) by heating on a water bath and the mixture was hot filtrated. In the filter residual brown-black bananin remained. The filtrate was slowly neutralized with a solution of 40.0 g sodium hydroxide (1 mol NaOH) in 200 mL water. Yellow bananin picrate precipitated. The precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl2) in a vacuum desiccator. Yield: yellow amorphous powder 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol picrate (bananin picrate).

Qualitative preparation of amorphous (SP-4-1)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O2,O3‘]copper [bananin copper complex, bis(bananinato)copper, bisBNcopper]

Suspension A: a saturated (room temperature θ=20 °C) solution of cupric sulfate pentahydrate (CuSO4·5H2O) in 100 mL of water was mixed with 100 mL of 1 M sodium hydroxide solution. Blue cupric hydroxide [Cu(OH)2] precipitated. Solution B: 50 mL of an at 80 °C saturated solution of 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) in 5 M sodium hydroxide solution. Freshly prepared suspension A was mixed with solution B and was cooled at +4 °C for 2 h. The light blue precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl2) in a vacuum desiccator. Yield: dark blue amorphous powder (SP-4-1)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O 2,O 3‘]copper [bananin copper complex, bis(bananinato)copper, bisBNcopper].

Qualitative preparation of amorphous (T-4)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O2,O3‘]zinc [bananin zinc complex, bis(bananinato)zinc, bisBNzinc]

Solution A: a saturated (room temperature θ=20 °C) solution of anhydrous zinc chloride (ZnCl2) in 10 mL of water. Solution B: 50 mL of an at 80° C saturated solution of 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol (bananin) in 5 M sodium hydroxide solution. Freshly prepared solution A was mixed with solution B and was cooled at +4° C for 2 h. The white precipitate was vacuum filtered and dried over anhydrous calcium chloride (CaCl2) in a vacuum desiccator. Yield: white amorphous powder (T-4)-bis[1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triolato(1-)-O 2,O 3‘]zinc [bananin zinc complex, bis(bananinato)zinc, bisBNzinc].